➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKesson
Boehringer Ingelheim
McKinsey
Baxter

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,369,077

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,369,077
Title:Multi chamber flexible bag and methods of using the same
Abstract: A method of preparing a pharmaceutical product in a single multiple chamber flexible bag. A pharmaceutical product is introduced in a liquid state into a first chamber of the flexible bag through a first port. The pharmaceutical product is lyophilized within the first chamber of the flexible bag to provide a lyophilized pharmaceutical product. The flexible bag has a second chamber and the first chamber and the second chamber are separated by a breakable seal. The second chamber further includes a reconstituting solution for reconstituting the lyophilized pharmaceutical product in the first chamber. A user may apply pressure to the flexible bag to break the seal and mix the lyophilized pharmaceutical product and the reconstituting solution to order to administer the pharmaceutical product to a patient.
Inventor(s): Di Naro; Antonio Francesco (Morcote, CH)
Assignee: ADIENNE PHARMA & BIOTECH SA (Lugano, CH)
Application Number:15/609,870
Patent Claims:1. A method of preparing a pharmaceutical product in a multiple chamber flexible bag, the method comprising: introducing the pharmaceutical product in a liquid state into a first chamber of the flexible bag through a first port; and lyophilizing the pharmaceutical product within the first chamber of the flexible bag to provide a lyophilized pharmaceutical product, wherein the flexible bag has a second chamber and the first chamber and the second chamber are separated by a breakable seal, and wherein the pharmaceutical product is a cytotoxic drug.

2. The method according to claim 1, further comprising introducing a reconstituting solution into the second chamber of the flexible bag.

3. The method according to claim 2, further comprising applying a predetermined amount of pressure to the flexible bag to break the breakable seal between the first chamber and the second chamber; and mixing the reconstituting solution with the lyophilized pharmaceutical product in the first chamber to create a reconstituted pharmaceutical product.

4. The method according to claim 3, further comprising administering the reconstituted pharmaceutical product to a patient through an administration port disposed in the flexible bag.

5. The bag according to claim 2, wherein the reconstituting solution is a 0.9% saline solution.

6. The method according to claim 1, further comprising introducing a gas into the first chamber and sealing the first port after the pharmaceutical product in the first chamber has been lyophilized.

7. The method according to claim 1, wherein the breakable seal is formed between the first chamber and the second chamber by joining a front surface of the flexible bag and a back surface of the flexible bag.

8. The method according claim 7, wherein the breakable seal comprises a weak point where the breakable seal is not as wide as the rest of the breakable seal, and wherein the breakable seal breaks at the weak point when pressure is applied to the flexible bag.

9. The bag according to claim 1, wherein the pharmaceutical product is an antineoplastic or an immunomodulating agent.

10. The bag according to claim 1, wherein the pharmaceutical product is selected from the group consisting of: azacytidine, belinostat, bendamustine, brentuximab vedotin, bleomycin, bortezomib, busulfan, carboplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, deferoxamine, doxorubicin, epirubicin hydrochloride, fludarabine, fotemustine, fulvestrant, gemcitabine, idarubicin, ifosfamide, irinotecan hydrochloride, ixabepilone, melphalan, methotrexate, oxaliplatin, paclitaxel, pemeterxed, pentostatin, raltitrexed, romidepsin, temozolomide, thiotepa, topotecan, trabectedin, trastuzumab, and vinblastine.

11. The method according to claim 1, wherein the flexible bag is fabricated from a polyolefine/styrene-block copolymer based film.

12. The method of claim 1, wherein the flexible bag does not contain rigid inserts during lyophilization.

13. The method of claim 1, wherein the flexible bag is not restrained by a structure during lyophilization.

14. A method of preparing a pharmaceutical product in a multiple chamber flexible bag, the method comprising: introducing the pharmaceutical product in a liquid state into a first chamber of the flexible bag through a first port; lyophilizing the pharmaceutical product within the first chamber of the flexible bag to provide a lyophilized pharmaceutical product; and sealing the first port after the pharmaceutical product in the first chamber has been lyophilized, wherein the pharmaceutical product is a cytotoxic drug, and wherein the flexible bag has a second chamber for introducing a reconstituting solution and wherein the first chamber and the second chamber are separated by a breakable seal.

15. The method according to claim 14, further comprising introducing a gas into the first chamber.

16. The method according to claim 14, further comprising applying a predetermined amount of pressure to the flexible bag to break the breakable seal between the first chamber and the second chamber; and mixing the reconstituting solution with the lyophilized pharmaceutical product in the first chamber to create a reconstituted pharmaceutical product.

17. The method according to claim 16, further comprising administering the reconstituted pharmaceutical product to a patient through an administration port disposed in the flexible bag.

18. The method according to claim 14, wherein the breakable seal is formed between the first chamber and the second chamber by joining a front surface of the flexible bag and a back surface of the flexible bag.

19. The method according claim 18, wherein the breakable seal comprises a weak point where the breakable seal is not as wide as the rest of the breakable seal, and wherein the breaking of the breakable seal initiates at the weak point when pressure is applied to the flexible bag.

20. The bag according to claim 14, wherein the pharmaceutical product is an antineoplastic or an immunomodulating agent.

21. The bag according to claim 14, wherein the pharmaceutical product is selected from the group consisting of: azacytidine, belinostat, bendamustine, brentuximab vedotin, bleomycin, bortezomib, busulfan, carboplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, deferoxamine, doxorubicin, epirubicin hydrochloride, fludarabine, fotemustine, fulvestrant, gemcitabine, idarubicin, ifosfamide, irinotecan hydrochloride, ixabepilone, melphalan, methotrexate, oxaliplatin, paclitaxel, pemeterxed, pentostatin, raltitrexed, romidepsin, temozolomide, thiotepa, topotecan, trabectedin, trastuzumab, and vinblastine.

22. The method according to claim 14, wherein the flexible bag is fabricated from a polyolefine/styrene-block copolymer based film.

Details for Patent 10,369,077

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial ADIENNE PHARMA & BIOTECH SA (Lugano, CH) 2039-08-20 RX Orphan search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125388 001 2011-08-19   Start Trial ADIENNE PHARMA & BIOTECH SA (Lugano, CH) 2039-08-20 RX Orphan search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125399 001 2011-08-19   Start Trial ADIENNE PHARMA & BIOTECH SA (Lugano, CH) 2039-08-20 RX search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial ADIENNE PHARMA & BIOTECH SA (Lugano, CH) 2039-08-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Medtronic
Merck
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.